A sustained-release didanosine formulation was developed as a matrix tablet prepared by direct compression using mixtures of Eudragit RSPM and Ethocel 100. Technological properties (mean weight, diameter, thickness and hardness) of tablets and in vitro drug release behaviour (USP basket apparatus) were determined. The effect of varying the Eudragit/Ethocel and the drug/polymeric matrix ratio, was evaluated. The results showed the suitability of Eudragit-Ethocel mixtures as matrix-forming material for sustained-release dosage forms and the possibility of suitably modulating the drug release rate by varying the drug/polymer ratio.
EUDRAGIT RS-PM-ETHOCEL 100 MATRIX TABLETS INTENDED FOR DIDANOSINE SUSTAINED RELEASE / C. Sànchez-Lafuente; M. Fernàndez-Arévalo; J. Alvarez-Fuentes; M.T. Faucci; F. Maestrelli; A.M Rabasco; P. Mura. - STAMPA. - (2001), pp. 333-336. (Intervento presentato al convegno NEW TRENDS IN POLYMERS FOR ORAL AND PARENTERAL ADMINISTRATION: FROM DESIGN TO RECEPTORS tenutosi a PARIS nel 12-13/03/2001).
EUDRAGIT RS-PM-ETHOCEL 100 MATRIX TABLETS INTENDED FOR DIDANOSINE SUSTAINED RELEASE
MAESTRELLI, FRANCESCA;MURA, PAOLA ANGELA
2001
Abstract
A sustained-release didanosine formulation was developed as a matrix tablet prepared by direct compression using mixtures of Eudragit RSPM and Ethocel 100. Technological properties (mean weight, diameter, thickness and hardness) of tablets and in vitro drug release behaviour (USP basket apparatus) were determined. The effect of varying the Eudragit/Ethocel and the drug/polymeric matrix ratio, was evaluated. The results showed the suitability of Eudragit-Ethocel mixtures as matrix-forming material for sustained-release dosage forms and the possibility of suitably modulating the drug release rate by varying the drug/polymer ratio.
I documenti in FLORE sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.
